Home/Eikonoklastes Therapeutics/Bruce Halpryn, PhD

BH

Bruce Halpryn, PhD

Chairman and Chief Executive Officer

Eikonoklastes Therapeutics

Therapeutic Areas

Neurodegenerative Diseases

Eikonoklastes Therapeutics Pipeline

Drug	Indication	Phase
ET-101 (SynCav1)	Amyotrophic Lateral Sclerosis (ALS)	Pre-clinical
ET-101 Platform	Parkinson’s, Huntington’s, MS, TBI, Alzheimer’s	Discovery

Leadership Team at Eikonoklastes Therapeutics

President and Chief Business Officer

View full Eikonoklastes Therapeutics profile